Xigris Side Effects

Generic name: drotrecogin alfa

Note: This document provides detailed information about Xigris Side Effects associated with drotrecogin alfa. Some dosage forms listed on this page may not apply specifically to the brand name Xigris.

Applies to drotrecogin alfa: intravenous powder for solution.

Serious side effects of Xigris

Along with its needed effects, drotrecogin alfa (the active ingredient contained in Xigris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking drotrecogin alfa:

More common side effects

• bleeding

For healthcare professionals

Applies to drotrecogin alfa: intravenous powder for injection.

General adverse events

The most common side effect associated with drotrecogin alfa (the active ingredient contained in Xigris) has been bleeding.^[Ref]

Hematologic

Hematologic side effects have most commonly included bleeding (25% vs 18% with placebo). The majority of events were ecchymoses or gastrointestinal tract bleeding. Serious bleeding has been reported in 3.5% of patients (vs 2% with placebo) and included intracranial hemorrhage, life threatening hemorrhage, and any event requiring 3 or more units of packed red blood cells per days for 2 consecutive days.^[Ref]

Serious bleeding events have been reported at the following sites: Gastrointestinal, intra-abdominal, intrathoracic, retroperitoneal, intracranial, genitourinary, skin or soft tissues.^[Ref]

Further information

Xigris side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer